Webcast Information Amylyx will host an investor event today, July 13, 2025, at 6:00 p.m. PT / 9:00 p.m. ET in San Francisco Will this drive upgrades tomm?
The stock market is knocking on the door of its third-priciest valuation multiple in history (during a continuous bull market), when back-tested over 154 years.There have been only six unique instances, dating back to January 1871, where the S&P 500's Shiller P/E ratio has surpassed 30 and held that mark for at least two months. Following the five prior occurrences, the Dow Jones Industrial Average, S&P 500, and/or Nasdaq Composite eventually plunged by 20% to 89%. Goldman Sachs Upgrades Amylyx Pharmaceuticals(AMLX.US) to Buy Rating, Raises Target Price to $10 News· Jul 10 16:31 · Guggenheim Initiates Amylyx Pharmaceuticals at Buy With $17 Price Target Published on 06/24/2025 at 07:31
AMLX Amylyx Pharmaceuticals, Inc. $7.68 0.29(+3.92%)4:00 PM 07/11/25 NASDAQ |$USD |Pre-Market:$8.04+0.36(+4.69%)7:33 AM
Immuneering Corporation(NASDAQ:IMRX) has been granted a U.S. composition of matter patent for atebimetinib, a once-daily oral cancer drug designed to overcome resistance and deliver longer-lasting benefits. In an ongoing Phase 2a study, the drug showed a 94% six-month survival rate in first-line pancreatic cancer—compared to 67% with standard care—while maintaining a strong safety profile. "Our priorities are to make medicines that keep working, so cancer patients keep living, and to make medicines that have fewer side effects, so cancer patients can feel like themselves and live normal lives," saidBen Zeskind, Ph.D., Co-founder and CEO of Immuneering. "We have already observed exceptional durability and a markedly favorable tolerability profile in first-line pancreatic cancer patients treated with atebimetinib+mGnP, and this is just the beginning of the important impact that we believe atebimetinib and our entire pipeline of deep cyclic inhibitors will have on the treatment of cancer." The patent provides exclusivity into 2042, with potential extension, supporting Immuneering's broader strategy to advance this "deep cyclic" MEK inhibitor across multiple tumor types.
Nuvation Bio Inc.(NYSE:NUVB) has announced that IBTROZI (taletrectinib)—its newly FDA-approved targeted therapy for advanced ROS1+ non-small cell lung cancer (NSCLC)—has now been added as a Preferred Agent in the latest National Comprehensive Cancer Network®(NCCN) Clinical Practice Guidelines. This designation applies to both first-line and follow-up treatment, and specifically highlights IBTROZI's benefit for patients with brain metastases and resistance mutations. "We are very pleased the NCCN acted with such urgency to review and update the NCCN Guidelines to include taletrectinib (IBTROZI) as a preferred option for advanced ROS1-positive NSCLC across treatment lines, with particular recognition of benefit for patients with brain metastases and those with acquired resistance after first-line therapy," saidDavid Hung, M.D., Founder, President and CEO of Nuvation Bio. "These updates address critical needs for patients across their treatment journeys, especially with the prevalence of CNS involvement for those living with ROS1+ NSCLC. Additionally, this version builds further upon a previous guideline update that importantly highlights preferred utilization of ROS1-targeted agents instead of immunotherapy and chemotherapy for these patients." The update strengthens IBTROZI's position as a next-generation treatment in a rare, aggressive lung cancer that often spreads to the brain. "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise" - Peter Lynch What is insider trading>> Time period 2025-06-18 Purchase 2025-06-18 4:05 pm Nuvation Bio Inc. NUVB Markel Stacy CHIEF PEOPLE OFFICER 10,000 $1.71 $17,100 29,591 (Direct) View 2025-06-16 Purchase 2025-06-18 4:05 pm Nuvation Bio Inc. NUVB Sauvage Philippe Chief Financial Officer 7,300 $1.8103 $13,216 9,902 (Direct) View 2025-06-16 Purchase 2025-06-18 4:05 pm Nuvation Bio Inc. NUVB Sjogren Colleen Chief Commercial Officer 50,000 $1.807 $90,350 81,000 (Direct) View 2025-06-16 Purchase 2025-06-18 4:05 pm Nuvation Bio Inc. NUVB Wentworth Kerry CHIEF REGULATORY OFFICER 50,000 $1.7948 $89,740 50,000 (Direct) View 2025-06-16 Purchase 2025-06-18 4:05 pm Nuvation Bio Inc. NUVB Hung David PRESIDENT AND CEO 10% Owner 500,000 $1.787 $893,500 59,281,054 (Direct) View
Stk was $1.92 on June 20-----::::::::: Nuvation Bio jumps after insiders purchase shares worth over $1.1M NewsFri, Jun. 20
It's weird watching absolutely everything I predicted come true. Fed Chair Powell may face dismissal over building renovation: Trump adviser Hassett
UPDATE- Both moderately up// not as good as silver plays. IMPUY = $9.70 SBSW Sibanye Stillwater Limited $8.26 0.32(+4.03%)
UPDATE- AMLX Amylyx Pharmaceuticals, Inc. $7.680.29(+3.92%)4:00 PM 07/11/25 NASDAQ |$USD |Pre-Market:$8.26+0.58(+7.55%)9:26 AM